Page 1

arrowhead pharmaceuticals Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results August 5 , 2021 Conference Call and Webcast Today , August 5 , 2021 at 4:30 p.m. ET PASADENA , Calif .-- ( BUSINESS WIRE ) -- Aug . 5 , 2021-- Arrowhead Pharmaceuticals , Inc. ( NASDAQ : ARWR ) today announced financial results for its fiscal third quarter ended June 30 , 2021. The company is hosting a conference call today , August 5 , 2021 , at 4:30 p.m. ET to discuss the results . Conference Call and Webcast Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call , please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7398304 . A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days . An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days . To access the audio replay , dial 855-859-2056 or 404-537-3406 and provide Conference ID 7398304 . Selected Recent Events • Received Breakthrough Therapy designation from the U.S. Food and Drug Administration for ARO - AAT , also known as TAK - 999 , the company's second - generation investigational RNA interference ( RNAi ) therapeutic being co - developed with Takeda Pharmaceutical Company Limited as a treatment for the rare genetic liver disease associated with alpha - 1 antitrypsin deficiency . • Presented additional positive interim 48 - week liver biopsy results from the ongoing AROAAT2002 study , an open - label Phase 2 clinical study of ARO - AAT , at The International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver ( EASL ) . The results demonstrate that investigational ARO - AAT treatment led to improvements in multiple measures of liver health , including fibrosis , with substantial and sustained reductions in the level of mutant AAT protein . In addition , ARO - AAT treatment was generally well tolerated after up to 1 year of treatment . • Presented positive interim results from AROHSD1001 , an ongoing Phase 1/2 clinical study of ARO - HSD , the company's investigational RNAi therapeutic being developed as a treatment for patients with alcohol - related and nonalcohol related liver diseases , such as nonalcoholic steatohepatitis ( NASH ) , at EASL . The data demonstrate that ARO - HSD is the first investigational therapeutic to achieve robust reductions in messenger RNA and protein levels of hepatic HSD17B13 , leading to reductions in alanine aminotransferase ( ALT ) , a liver enzyme typically elevated in liver diseases including NASH . • Announced positive interim results from the first two cohorts of AROHIF21001 , a Phase 1b dose - finding clinical study of ARO - HIF2 , the company's investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma . The data show clear signs of meaningful target engagement and some potentially early signs of efficacy in at least one patient . • Initiated and began dosing patients in AROANG3-2001 , a Phase 2b clinical study of ARO - ANG3 , the company's investigational RNAi therapeutic being developed as a treatment for patients with mixed dyslipidemia . • Initiated and began dosing patients in AROAPOC3-2001 , a Phase 2b clinical study of ARO - APOC3 , the company's investigational RNA interference ( RNAi ) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia ( SHTG ) . Arrowhead also intends to initiate a Phase 2b study and a Phase 3 study of ARO - APOC3 in two additional patient populations in 2021 . • Announced a global collaboration and license agreement with Horizon Therapeutics for ARO - XDH , a previously undisclosed discovery - stage RNAi therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout . Arrowhead received $ 40 million as an upfront payment from Horizon and is eligible to receive up to $ 660 million in potential development , regulatory and commercial milestones , and is further eligible to receive royalties in the low- to mid - teens range on net product sales . • Earned a $ 10 million option exercise fee from Janssen Pharmaceuticals , Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , for ARO - JNJ1 . • Presented promising preclinical data on ARO - DUX4 , Arrowhead's first muscle - targeted program being developed as a treatment for patients with facioscapulohumeral muscular dystrophy ( FSHD ) at the 28th Annual FSHD Society International Research Congress . The data show that the TRIM ™ muscle delivery platform achieved functional delivery to various types of skeletal muscle and achieved deep , durable , and dose - dependent knockdown of target genes . In addition , ARO - DUX4 improved multiple measures of FSHD - like muscle phenotype in relevant preclinical animal models . • Nominated ARO - C3 , which is designed to reduce production of complement component 3 ( C3 ) as a potential treatment for various complement mediated diseases , as a clinical candidate and initiated IND - enabling toxicology studies .